S452
Clinical - Gynaecological
ESTRO 2026
shown in Figure2. The 1-/2-year OSAF for the entire failed cohort was 33%/59%, with a median survival after failure (MSAF) of 15 months. By failure pattern, LRF only MSAF was longer than DM only (13 months) and DM+LRF (14 months), but the difference was not statistically significant (p=0.217). No difference in OSAF was observed between RW vs EMBRACE. Conclusion: Real-World LACC patients treated with modern radiotherapy achieved favourable and comparable outcomes to the benchmark EMBRACE II in our institution. Without differences in failure pattern between cohorts, the survival after failure was better for patients with LRF only. Keywords: Cervix, Realworld, IGABT Digital Poster 2428 Real-world surveillance patterns in gynaecological cancers: Insights from the Y-ECI EORTC survey. Noelia Sanmamed salgado 1 , Eva Oldenburger 2 , Melpomeni Kountouri 3 , Stefania Rizzo 4 , Gloria Marquina 5 , Reyes Oliver 6 , Javier Prato 7 , Elena Cerezo 1 , Giorgio Bogani 8 , Judith Kroep 9 , Fernanda Herrera 10 , Ainhoa Madariaga 11 1 Radiation Oncology, Hospital clinico San Carlos, Madrid, Spain. 2 Radiation Oncology, University Hospitals Leuven, Leuven, Belgium. 3 Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. 4 Radiology, Ente Ospedaliero Cantonale, Lugano, Switzerland. 5 Medical Oncology, Hospital clinico San Carlos, Madrid, Spain. 6 Gynecology, Hospital Doce de Octubre, Madrid, Spain. 7 Medical Oncology, Hospital Universitario HLA Moncloa, Madrid, Spain. 8 Gynecology, Istituto Nazionale Tumori, Milan, Italy. 9 Medical Oncology, Leiden University Medical Center, Leiden, Netherlands. 10 Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland. 11 Medical Oncology, Hospital Doce de Octubre, Madrid, Spain
Purpose/Objective: To assess current surveillance practices for patients with gynaecological malignancies (GM) among different countries and clinical settings, and to identify areas of variability in follow-up (FU) strategies across tumour types. Material/Methods: The Young & Early Career Investigators (Y-ECI) of the European Organization of Research and Treatment of Cancer (EORTC) conducted an online survey between October 2024 and October 2025 to evaluate FU patterns in GM. An online questionnaire was distributed to members of several national and international professional societies in gynaecological oncology, medical oncology, radiation oncology, and related disciplines. Collected data collected included clinician demographics, institutional characteristics, and FU practices for ovarian (OC), cervical (CC), and endometrial cancer (EC). Results: A total of 183 clinicians participated: 53 radiation oncologists (29%), 51 medical oncologists (28%), 46 gynaecologic oncologists (25%), 20 gynaecologists (11%), and 13 from other specialties (7%). Most respondents worked in university (55%) or specialised oncological hospitals (31%), and were based in Europe (83%). The majority was female (65%) and had more than five years of clinical experience (82%). During FU tumour markers were routinely used by 80% in OC, 37% in CC, and 28% in EC. Routine imaging was most frequent in OC (70%; with 93% using CT), compared with CC (52%; with 49% CT and 43% MRI) and EC (34%; with 75% CT). Pap testing was non routinely performed in OC, but was used in 64% for CC and 52% for EC, with variable frequency (ranging from each visit to annual testing). HPV testing was used by 51% for CC, most commonly yearly (33%). Consensus was highest for FU
Made with FlippingBook - Share PDF online